CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Medical Meeting
Dermabase.it
Farmaexplorer.it

Search results for "Embolism"

The prolonged immobility of flight passengers during long-haul air travel increases the risk of developing blood clots, which could prove fatal especially to people whose travel occurs just prior to m ...


FDA ( Food and Drug Administration ) approved the supplemental New Drug Application (sNDA) for Arixtra ( Fondaparinux ) in the prevention of venous thromboembolism ( VTE ) in patients undergoing abd ...


The American College of Chest Physicians ( ACCP ) released the first evidence-based clinical practice guidelines for the prevention and management of postoperative atrial fibrillation ( AF ) after car ...


Risk factors for stroke should be used to determine whether anti-clotting therapy is given to people with atrial fibrillation, according to revised Guidelines for the Management of Patients with Atria ...


The Phase III EINSTEIN-DVT clinical trial of the oral anticoagulant Rivaroxaban ( Xarelto ) demonstrated non-inferiority compared to the standard of care for the prevention of recurrent venous thrombo ...


Results from the phase III STARS J-V ( Studying Thrombosis After Replacement Surgery ) study have shown Edoxaban ( Lixiana ), a direct factor Xa inhibitor, to be superior to Enoxaparin ( Lovenox ) in ...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product Xarelto ( Riva ...


The four-year follow-up data from the PROTECT AF clinical trial demonstrated the Watchman Left Atrial Appendage ( LAA ) Closure device was statistically superior to Warfarin ( Coumadin ) for preventin ...


The options for secondary prevention of cryptogenic embolism in patients with patent foramen ovale are administration of antithrombotic medications or percutaneous closure of the patent foramen ovale. ...


Apixaban ( Eliquis ), an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism.In the randomized, double-blind study ( AMPLIFY ), researchers have ...


Edoxaban ( Savaysa ) is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of Edoxaban as compared with Warfarin ( Coumadin ) in patients with atri ...


Anticoagulant treatment with vitamin K antagonists ( VKAs ) is aimed at preventing thromboembolic complications and has been the therapy of choice for most people with non-valvular atrial fibrillation ...


For patients with atrial fibrillation or atrial flutter of 48-hour duration or longer, or when the duration of atrial fibrillation is unknown, anticoagulation with Warfarin ( INR 2.0 to 3.0 ) is recom ...


Bristol-Myers Squibb ( BMS ) and Pfizer have announced results of a pre-specified subanalysis of the phase 3 ARISTOTLE trial in relation to patient age. ARISTOTLE was designed to evaluate the effica ...


An observational study has attempted to identify appropriate elements that may contribute to clarify the broad clinical features ( diagnosis, care, complication and prognosis ) of Takotsubo-like cardi ...